Boreal Ventures will invest in deep tech companies emerging from ÉTS Montréal’s incubator Centech and the wider Quebec ecosystem.

Legend Capital has returned to invest in the metabolic and immunological disease-focused biotechnology developer, having backed its series A round two years ago.

MIT’s cancer and infectious disease therapy spinout has added $40m to a round that will support the progression of its lead asset into the clinic.

Xfund is among the backers of a $17m round for ImmuneID, which has been set up to commercialise research from Harvard University and Johns Hopkins University.

The JD.com, Shanghai Pharma and SoftBank China Venture Capital-backed O2O medical services operator, has secured fresh funding from investors including Sinocare.

The Qilu Pharmaceutical-backed cancer, immune disorder and metabolic disease drug developer has closed a series B round led by Lilly Asia Ventures.

The Livzon-backed cancer and infectious disease therapy developer has added $40m to a round that will support the progression of its lead candidate toward clinical trials.

Girish Hiremath, chief operating officer at Ginserv, said being part the Mysuru-based JSS group would be a help to the startups.

Advent Life Sciences will manage an impact investment vehicle for Harrington Discovery Institute.

MedPilot, a developer of healthcare revenue management software, has been acquired after raising $3.6m from backers including Cedars-Sinai Accelerator.